Clinical trials: Nonalcoholic Steatohepatitis
Steatohepatitis, Nonalcoholic, Steatosis
Nutritional Intervention IN Nash NON-ALCOHOLIC (NAFLD).
The goal of this randomized clinical trial with adults is to discuss the effectiveness of the nutritionist's educational interventions in users diagnosed with NAFLD, compared to the usual medical follow-up of users treated at the…
- Conditions
- Steatohepatitis, Nonalcoholic, Steatosis, Liver Diseases, Steatohepatitis
- Trial name
- NUTRINAFLD (NCT05946330)
- Testing
- NUTRITIONAL EDUCATIONAL INTERVENTION IN FATTY LIVER DISEASE NON-ALCOHOLIC (NAFLD).
- Where
- Brazil
- Volunteers
- 10 people
- Sponsor
- Universidade Federal do Paraná
Fatty Liver, Hepatitis
Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH)
The purpose of this study is to determine if orlistat (Xenical) therapy in overweight patients with NASH leads to enhanced weight loss over time, with subsequent improvement in the underlying necroinflammatory and fibrotic…
- Trial name
- NCT00160407
- Testing
- Orlistat (Xenical), 1400 kcal diet (30% fat)
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- St. Louis University
Transient Elastography, MASLD
Hepatic Elastography-Enhanced Lifestyle Modification in MASLD
The 2022 National Health Survey in Thailand revealed a substantial rise in obesity and metabolic dysfunction-associated steatotic liver disease (MASLD).
- Conditions
- Transient Elastography, MASLD, BMI, Metabolic Syndrome
- Trial name
- NCT06826807
- Testing
- Regular monitoring with transient elastography
- Where
- Thailand
- Volunteers
- 92 people
- Sponsor
- Mahidol University
NASH - Nonalcoholic Steatohepatitis, Liver Fibroses
Liquid Biopsy for NASH and Liver Fibrosis
Nonalcoholic fatty liver disease (NAFLD) has evolved to represent the most common cause of chronic liver disease globally. Today, NAFLD is a leading indication for liver transplantation and a major etiology for hepatocellular…
- Trial name
- LIBRA (NCT04677101)
- Testing
- Liver Biopsy
- Where
- 2 sites in Italy
- Volunteers
- 150 people
- Sponsor
- Catholic University of the Sacred Heart
NAFLD, Type 1 Diabetes
Prevalence, Incidence and Characteristics of NAFLD/NASH in Type 1 Diabetes Mellitus
Nonalcoholic fatty liver disease (NAFLD) is a condition characterized by intrahepatic fat accumulation. It is closely related to insulin resistance.
- Conditions
- NAFLD, Type 1 Diabetes, Cardiovascular Diseases
- Trial name
- NAFLDIA1 (NCT04664036)
- Testing
- ultrasound, elastography, controlled attenuation parameter (CAP)
- Where
- Belgium
- Volunteers
- 700 people
- Sponsor
- University Hospital, Antwerp
Fatty Liver, Non-alcoholic Fatty Liver Disease, NAFLD
A Study of RO5093151 in Patients With Non-Alcoholic Fatty Liver Disease
This multi-center, double-blind, randomized, placebo-controlled study will evaluate the change in liver fat content, pharmacokinetics and safety of RO5093151 in patients with non-alcoholic fatty liver disease.
- Trial name
- NCT01277094
- Testing
- RO5093151
- Where
- 4 sites in Austria, Germany
- Volunteers
- 82 people
- Sponsor
- Hoffmann-La Roche
Nonalcoholic Fatty Liver Disease
The Study of Multiple Doses of CM-101 in Male and Female NAFLD (Nonalcoholic Fatty Liver Disease) and NAFLD/NASH (Nonalcoholic Steatohepatitis) Subjects
A two-part study for NAFLD subjects with normal liver functions and in general good health to be treated with CM-101 or matching placebo and NAFLD/NASH Activity Score (NAS) < 3 that are in general good health and have normal…
- Trial name
- NCT06044467
- Testing
- Anti-human CCL24 monoclonal antibody (CM-101) - Part One, Anti-human CCL24 monoclonal antibody (CM-101) - Part Two
- Where
- Israel
- Volunteers
- 16 people
- Sponsor
- ChemomAb Ltd.
Liver Transplant; Complications, Diabetes Mellitus
Semaglutide vs Sitagliptin
The effect of once daily dosing of oral Semaglutide versus once daily dosing Sitagliptin on glycemic control, body weight, and safety and tolerability will be compared in Liver Transplant Recipients with poorly-controlled…
- Conditions
- Liver Transplant; Complications, Diabetes Mellitus, NASH - Nonalcoholic Steatohepatitis, NAFLD
- Trial name
- NCT05195944
- Testing
- Semaglutide Treatment, Sitagliptin 100mg
- Where
- Canada
- Volunteers
- 58 people
- Sponsor
- University Health Network, Toronto
Liver Fibrosis, Malnutrition
Nutritional Indices and Inflammatory Markers in MASLD
Metabolic Dysfunction-Associated steatotic Liver Diseases MASLD affects approximately 25 percent of population. Systemic inflammation plays role in MASLD progression.
- Conditions
- Liver Fibrosis, Malnutrition, Non-Alcoholic Fatty Liver Disease
- Trial name
- NCT07834905
- Volunteers
- 180 people
- Sponsor
- Assiut University
Cardiovascular Diseases, Non-Alcoholic Fatty Liver Disease
Smart Watch Insights for Prevention of Exacerbations and Enhance Rehabilitation - Movement Study
Aims of the study: 1. To deliver a scalable wellbeing programme to the local population of Imperial College Healthcare NHS Trust, focusing on movement. 2.
- Conditions
- Cardiovascular Diseases, Non-Alcoholic Fatty Liver Disease, Respiratory Disease, Diabetes
- Trial name
- SWIPER-MOVES (NCT06011356)
- Testing
- Smartwatch
- Where
- United Kingdom
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis
The Olmsted NAFLD Epidemiology Study (TONES)
Researchers are assessing the prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH) in the population and assembling a well-characterized cohort of adults with NAFLD and NASH to validate…
- Trial name
- NCT04365855
- Testing
- Magnetic Resonance Elastography, Blood draw, Liver biopsy
- Where
- United States
- Volunteers
- 800 people
- Sponsor
- Mayo Clinic
Diabetes Mellitus, Type 2
Evaluation of the Integrated Radio Frequency Denervation System to Improve Glycemic Control in Type 2 Diabetic Subjects
The objective of this early feasibility study is to evaluate the safety and performance of intravascular hepatic denervation using the Metavention Integrated Radio Frequency Denervation System (iRF System) to improve glycemic…
- Trial name
- DeLIVER (NCT04285554)
- Testing
- iRF System Hepatic Denervation
- Where
- 8 sites in United States
- Volunteers
- 15 people
- Sponsor
- Metavention
Non-Alcoholic Steatohepatitis
A Study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
The purpose of this study is to determine whether BMS-986036 is effective in the treatment of subjects with Non-alcoholic Steatohepatitis (NASH).
- Trial name
- NCT02413372
- Testing
- BMS-986036
- Where
- 17 sites in United States
- Volunteers
- 184 people
- Sponsor
- Bristol-Myers Squibb
Metabolic Associated Fatty Liver Disease
Benefits of Trimetazidine in MASLD Patients
Objective of this study is to determine the clinical benefits of trimetazidine in improvement of MASLD
- Trial name
- MASLD (NCT06140953)
- Testing
- Trimetazidine, Conventional therapy
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- October 6 University
Fatty Liver
Cilostazol in the Treatment of Nonalcoholic Fatty Liver Disease
Nonalcoholic fatty liver disease (NAFLD) is a global public health concern, and the leading cause of chronic liver disease, especially in developed countries (1).
- Trial name
- NCT07238985
- Testing
- Standard therapy, Cilostazol
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Tanta University
Nonalcoholic Steatohepatitis
JKB-121 for the Treatment of Nonalcoholic Steatohepatitis
To evaluate the safety and potential efficacy of two dose levels of JKB-121 (5 mg twice daily and 10 mg twice daily) in reducing liver fat and/or liver biochemistry compared to placebo in patients with biopsy-proven nonalcoholic…
- Trial name
- NCT02442687
- Testing
- JKB-121: 5 mg twice daily, JKB-121: 10 mg twice daily
- Where
- 8 sites in United States
- Volunteers
- 65 people
- Sponsor
- Manal Abdelmalek
Nonalcoholic Steatohepatitis (NASH), Nonalcoholic Fatty Liver Disease (NAFLD)
Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH)
The primary objective of this study is to evaluate the safety and tolerability of selonsertib, firsocostat, cilofexor, fenofibrate and/or Vascepa® in adults with nonalcoholic fatty liver disease (NAFLD) or nonalcoholic…
- Trial name
- NCT02781584
- Testing
- SEL, FIR, CILO
- Where
- 13 sites in United States, New Zealand
- Volunteers
- 220 people
- Sponsor
- Gilead Sciences
Non-Alcoholic Fatty Liver Disease, Non Alcoholic Steatohepatitis
Fecal Microbiota Transplantation for the Treatment of Non-Alcoholic Steatohepatitis
Human microbiota is the set of microorganisms that, in a symbiotic way, coexist and develop in the different surfaces (skin and mucous membranes) of the human body.
- Trial name
- FMT-NASH (NCT03803540)
- Testing
- Fecal Microbiota Transplantation
- Where
- Spain
- Volunteers
- 15 people
- Sponsor
- Puerta de Hierro University Hospital
Prediabetic State, Non-alcoholic Fatty Liver Disease
ORION: Effects of Cenicriviroc on Insulin Sensitivity in Subjects With Prediabetes or Type 2 Diabetes Mellitus (T2DM) and Suspected NAFLD
A Phase 2a, randomized, double-blind, placebo-controlled, multi-center study of cenicriviroc (CVC) to be conducted in approximately 50 adult obese subjects [body mass index (BMI) ≥ 30 kg/m^2] with prediabetes or type 2 diabetes…
- Conditions
- Prediabetic State, Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus
- Trial name
- NCT02330549
- Testing
- Cenicriviroc 150 mg
- Where
- 3 sites in United States, Puerto Rico
- Volunteers
- 45 people
- Sponsor
- Tobira Therapeutics, Inc.
Metabolic Dysfunction-Associated Steatotic Liver Disease
Digital Diet and Exercise Intervention to Reduce Liver Fibrosis in Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)
Study Title: Digital Diet and Exercise Intervention to Reduce Liver Fibrosis in Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Randomized Controlled Trial (D-FIB-MASLD) Objective: This study aims to assess…
- Trial name
- DEFIB-MASLD (NCT06920316)
- Testing
- Gro Health digital application
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- St. George's Hospital, London
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.